References:
- Bishop JR. Pharmacogenetics.Handb Clin Neurol. 147:59-73 (2018).
- Nebert DW. Pharmacogenetics and pharmacogenomics: why is this relevant
to the clinical geneticist? Clinical Genetics. 56: 247-258
(1999).
- European Medicine Agency. Position paper on terminology in
pharmacogenetics discussion at the pharmacogenetics expert group. Eur
Med Agency - Comm Propr Med Prod [Internet]. (November):0–6.
(2001) Available from: http://www.emea.eu.int. Accessed on 28
May 2020.
- Jain KK. Personalized medicine. Curr Opin Mol Ther. 4(6):548–58
(2002).
- Mirsadeghi S, Larijani B.
Personalized Medicine: Pharmacogenomics and Drug Development.Acta Med Iran . 55(3):150‐165 (2017).
- Meyer UA. Drugs in special
patient groups: clinical importance of genomics in drug effects. In:
Carruthers GS, Hoffmann BB, Melmon KL, Nierenberg DW, eds. New York:
McGrawHill, 1179–205 (2000).
- Ingelman-Sundberg M.
Pharmacogenetics: an opportunity for a safer and more efficient
pharmacotherapy. J Intern Med 250(3):186‐200 (2001).
- Evans WE, Relling MV. Pharmacogenomics: translating functional
genomics into rational therapeutics. Science 286: 487–91
(1999).
- Roses AD. Pharmacogenetics and
future drug development and delivery. Lancet 355: 1358–61
(2000).
- Ingelman-Sundberg M, Sim SC,
Gomez A, Rodriguez-Antona C. Influence of cytochrome P450
polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic
and clinical aspects. Pharmacol Ther 116(3):496‐526 (2007).
- Food and Drug Administration. Table of pharmacogenomic biomarkers in
drug labels [Internet] Springfield, MD: The Administration; Jun 6
2013 [cited 5 May 2020].
https://www.fda.gov/drugs/science-and-research-drugs/table-pharmacogenomic-biomarkers-drug-labeling
Accessed on 28 May 2020.
- Shoshi A, Müller U, Shoshi A, Ogultarhan V, Hofestädt R. KALIS - An
eHealth System for Biomedical Risk Analysis of Drugs. Stud
Health Technol Inform. 236:128-135 (2017).
- Weinshilboum RM, Wang L. Pharmacogenomics: Precision Medicine and Drug
Response. Mayo Clin Proc. 92(11):1711‐1722 (2017).
- Eichelbaum M, Ingelman-Sundberg
M, Evans WE. Pharmacogenomics and individualized drug therapy.Annu Rev Med . 57:119‐137 (2006).
- Shepherd G, Mohorn P, Yacoub K, May DW. Adverse drug reaction deaths
reported in United States vital statistics, 1999-2006. Ann
Pharmacother . 46(2):169‐175 (2012).
- Pirmohamed M, James S, Meakin S,
et al. Adverse drug reactions as cause of admission to hospital:
prospective analysis of 18 820 patients. BMJ (Clinical research
ed.) 329(7456), 15–19 (2004).
- Guideline on summary of product
characteristics (SmPC). European commission enterprise and industry
directorate-general. European Commission. https://ec.europa.eu/health/
sites/health/files/files/eudralex/vol-2/c/smpc_guideline_rev2_en.pdf.
(2009). Accessed 5 May 2020.
- Ehmann F, Caneva L, Prasad K, et
al. Pharmacogenomic information in drug labels: European Medicines
Agency perspective. Pharmacogenomics J. 15(3):201-10. doi:
10.1038/tpj.2014.86 (2015).
- Frueh FW, Amur S, Mummaneni P,
et al. Pharmacogenomic biomarker information in drug labels approved
by the United States Food and Drug Administration: prevalence of
related drug use. Pharmacotherapy. 28(8):992–998 (2008).
- The SmPC of the drugs approved
by TDMDA, https://www.titck.gov.tr/kubkt. Accessed on 14 April
2020.
- RX Media Pharma Interactive
Pharmaceuticals Information Source https://www.eczanet.com/.
Accessed on 14 April 2020.
- PharmGKB Drug label annotations.
https://www.pharmgkb.org/labelAnnotations. Accessed on 14 April
2020.
- Haga SB, Mills R, Moaddeb J.
Pharmacogenetic information for patients on drug labels.Pharmgenomics Pers Med. 7:297-305 (2014).
- Pai SA, Kshirsagar N. A Critical
Evaluation of Pharmacogenetic Information in Package Inserts for
Selected Drugs Marketed in India and Its Comparison With US
FDA-Approved Package Inserts. J Clin Pharmacol. 56(10):1232-42
(2016).
- Reis-Pardal J, Rodrigues A, Rodrigues E, Fernandez-Llimos F. Comparing
cytochrome P450 pharmacogenetic information available on United States
drug labels and European Union Summaries of Product Characteristics.Pharmacogenomics J. 17(6):488-493 (2017).
- Schuck RN, Grillo JA. Pharmacogenomic Biomarkers: an FDA Perspective
on Utilization in Biological Product Labeling. AAPS J.18(3):573-7 (2016).
- Zhu Q, Freimuth RR, Pathak J,
Durski MJ, Chute CG. Disambiguation of PharmGKB drug-disease relations
with NDF-RT and SPL. J Biomed Inform. 46(4):690-6 (2013).
- Preskorn SH, Hatt CR. How
pharmacogenomics (PG) are changing practice: implications for
prescribers, their patients, and the healthcare system (PG series part
I). J Psychiatr Pract. 19(2):142-9 (2013).
- Haga SB, Thummel KE, Burke W.
Adding pharmacogenetics information to drug labels: lessons learned.Pharmacogenet Genomics. 16(12):847-54 (2006).
- Shekhani R, Steinacher L, Swen
JJ, Ingelman-Sundberg M. Evaluation of Current Regulation and
Guidelines of Pharmacogenomic Drug Labels: Opportunities for
Improvements. Clin Pharmacol Ther. 107(5):1240-1255 (2019).
- Tan-Koi WC, Leow PC, Teo YY.
Applications of pharmacogenomics in regulatory science: a product life
cycle review. Pharmacogenomics J. 18(3):359-366 (2018).
- Beauchamp TL, Childress JF.
Principles of biomedical ethics. 5th ed. New York Oxford University
Press; 57-103 (2001).
- Brezis M, Israel S,
Weinstein-Birenshtock A et al. Quality of informed consent for
invasive procedures. Int J Qual Health Care . 20(5):352-357
(2008).
- Kureshi F, Jones PG, Buchanan
DM, Abdallah MS, Spertus JA. Variation in patients’ perceptions of
elective percutaneous coronary intervention in stable coronary artery
disease: cross sectional study. BMJ 349: g5309 (2014).
- Rose D, Russo J, Wykes T. Taking
part in a pharmacogenomic clinical trial: assessment of trial
participants understanding of information disclosed during the
informed consent process. BMC Med Ethics. 14:34 (2013).
- Madadi P. Ethical Perspectives
on Translational Pharmacogenetic Research Involving Children.Pediatr Drugs 17:91–95 (2015).
- Zakinova A, Long-Boyle JR,
French D, et al. A Practical First Step Using Needs Assessment and a
Survey Approach to Implementing a Clinical Pharmacogenomics Consult
Service. J Am Coll Clin Pharm. 2(3):214‐221 (2019).
- Elewa H, Alkhiyami D, Alsahan D, Abdel-Aziz A. A survey on the
awareness and attitude of pharmacists and doctors towards the
application of pharmacogenomics and its challenges in Qatar. J
Eval Clin Pract. 21(4):703‐709 (2015).
- Amara N, Blouin-Bougie J,
Bouthillier D, Simard J. On the readiness of physicians for
pharmacogenomics testing: an empirical assessment.Pharmacogenomics J. 18(2):308‐318 (2018).
- Chua EW, Kennedy MA. Current
state and future prospects of direct-to-consumer pharmacogenetics.Front. Pharmacol. 3:152 (2012).